Guardant Health acquires MetaSight Diagnostics Ltd.

Guardant Health acquired MetaSight Diagnostics Ltd. for $93.0 million total purchase consideration net of cash ($59.0 million upfront cash plus up to $90.0 million contingent; $34.0 million contingent fair value at acquisition date), a transaction completed in December 2025, structured as cash plus contingent consideration.

MetaSight Diagnostics Ltd. operates in Liquid-biopsy diagnostics technology / early cancer and disease detection, is based in Israel (founded 2020 via a partnership between healthtech fund aMoon and the Technion - Israel Institute of Technology). In December 2025 Guardant Health purchased all of the outstanding shares of MetaSight Diagnostics Ltd., a health technology company. The transaction included $59.0 million in upfront cash consideration paid at closing, plus up to $90.0 million in variable contingent consideration tied to future commercial performance and regulatory approvals of the MetaSight technology. Total purchase consideration net of cash acquired was $93.0 million, with the contingent consideration carried at a fair value of $34.0 million as of the acquisition date. The excess of purchase consideration over the fair value of net assets acquired was recorded as goodwill, attributable to future revenue opportunities Guardant expects from leveraging the acquired technologies.

Goodwill is attributable to future revenue opportunities that the Company expects to achieve from leveraging the acquired technologies.

MetaSight's next-generation liquid biopsies are designed for population-level early detection of cancer and other diseases, with potential to enhance testing performance across Guardant's portfolio. Acquired technologies expected to support future revenue opportunities and strengthen Guardant's early-detection and screening portfolio.